Skip to main content

Cardio/Pulmonary

RheumNow Podcast – I Wanna New Drug.V2 (9.24.2021)

Sep 23, 2021

Almost three years ago to the day, I did a podcast entitled, "I wanna new drug." As I go over this week's podcast, I want to say it again. I want a new drug safe enough to use during pregnancy, for PMR, for GVHD, and more. I'm going to cover these, and other topics including lupus, COVID

Read Article

High Comorbidity Rates with Inclusion Body Myositis

Sep 21, 2021

Inclusion body myositis (IBM) patients tend to be older than those with idiopathic inflammatory myositis (IIM), but the scope of disease beyond their myositis is not appreciated. Now, a population-based, case-control study suggests both a lower overall survival and high comorbidity burden in

Read Article
Claims case-controlled study shows statin use does not increase the risk of #RA - 32,726 RA and matched controls ; statin use (34 vs 32%) slightly increased RA risk (OR 1.12, 1.06–1.18), but signif lost after correcting for hyperlipidemia https://t.co/EcTlyE1MPx

Dr. John Cush @RheumNow( View Tweet )

Sep 20, 2021
"In medical school, they spend days teaching people to operate on lungs, and no time at all helping young doctors learn how to get their patients to stop smoking and get vaccinated." - Seth Godin https://t.co/YIk0O0kDTB

Dr. John Cush @RheumNow( View Tweet )

Sep 20, 2021

RheumNow Podcast – Do More DMARDs Mean More Switching? (9.17.2021)

Sep 16, 2021

Smartphones and diet; COVID-19 and the numbers - reassuring or not, and what about masks?; and do more drugs mean more switching, less persistence, and patient adherence goes up...or down? All this and more news and journal reports in this week's episode.

Read Article
Popular read— FDA: New Cardiac and Cancer Warnings for All JAK Inhibitors https://t.co/jayl8ufPHn

Dr. John Cush @RheumNow( View Tweet )

Sep 16, 2021

Pneumocystis Often Lethal in Dermatomyositis

MedPage Today
Sep 14, 2021

Patients with dermatomyositis who were positive for a myositis-specific antibody had a much higher incidence of and mortality associated with Pneumocystis jirovecii infection than patients with other antibody-negative idiopathic inflammatory myopathies, Chinese researchers found.

Read Article

ACR Comments on JAK Inhibitors and FDA Announcement

ACR
Sep 13, 2021

Following is a statement from ACR President David Karp, MD, PhD, on JAK inhibitors and FDA drug safety communication.

Read Article
A retrospective study of systemic sclerosis patients shows that acute hospitalization and mortality were not uncommon and were often linked to SSc-related lung disease. #RheumNow https://t.co/s5wSlndTrt https://t.co/KHz9LYZVAK
Dr. John Cush @RheumNow( View Tweet )
Sep 10, 2021

RheumNow Podcast – High Science and Future Treatments (9.10.2021)

Sep 10, 2021

This week: high science that affect future treatments; breakthrough infections in our patients, and what's up with that; and soon your radiologist is going to be replaced by AI. This and more in our review of the news and journal articles from the past week.

Read Article

FDA Review of Vaping Products Extended

Sep 09, 2021

The FDA has again extended its decision on whether the manufacturers of vaping products can market their e-cigarettes in the United States.



Previously, the manufacturers (Juul, Vuse and Blu) were given until September 2020 to submit data to the FDA on the use and safety of these

Read Article

Risk Factors Associated with Systemic Sclerosis Hospitalization

Sep 09, 2021

A retrospective study of systemic sclerosis patients shows that acute hospitalization and mortality were not uncommon and were often linked to SSc-related lung disease.



Record review of 95 SSc patients from a single-centre cohort seen between 2010 and 2020 found that over half (53

Read Article
Cardiac coronary Ca score (CCS) in 20 asymptomatic systemic sclerosis (SSc) pts vs controls.CCS incr (& higher scores) in 45% SSc vs 10% controls. CCS values higher in Limited vs diffuse SSc. CCS > 100 assoc w/ age, dz duration obesity https://t.co/aDWpoePqXK

Dr. John Cush @RheumNow( View Tweet )

Sep 09, 2021

Expert Panel: Initial Views on FDA Warnings for JAK Inhibitors

Sep 02, 2021

Dr. Jack Cush is joined by Drs. Roy Fleischmann (Dallas), Allan Gibofsky (NYC), and Artie Kavanaugh (San Diego) to discuss the 9/2/21 FDA Drug Safety Communication regarding the cardiovascular and cancer risks arising from the Pfizer 1133 (ORAL Surveillance) tofacitinib study, but also applied

Read Article
The FDA announced its findings regarding tofacitinib's safety concerns from the Oral Surveillance study - handing down warnings for not only Pfizer's JAK inhibitor, but also for other marketed JAK inhibitors from AbbVie and Eli Lilly & Co. https://t.co/jayl8ufPHn https://t.co/zNvPiVcdOM
Dr. John Cush @RheumNow( View Tweet )
Sep 02, 2021
Newly Revised Xeljanz Boxed Warning. New Changes highlighted in yellow. https://t.co/jayl8tYeiN https://t.co/5tXX00UgBD
Dr. John Cush @RheumNow( View Tweet )
Sep 01, 2021

Passive Smoke Exposure and Rheumatoid Risk

Aug 23, 2021

A current report in Arthritis & Rheumatology examined the Nurses Health Study II data set and shows that parental smoking, and passive exposure to children, can later lead to an increased risk of adult-onset incident seropositive rheumatoid arthritis (RA).

Read Article

RheumNow Podcast – Driving in Pain (8.20.2021)

Aug 20, 2021

You know, I'm a very good driver. We all think we're great drivers - but consider what it's like to drive in pain: would you be a good driver? Also, I want you to consider the diagnosis of calcium pyrophosphate dihydrate disease (CPPD). But first, let's look at a study out of Scotland, looking

Read Article

EULAR Points on Managing Difficult Rheumatoid Arthritis

Aug 19, 2021

A EULAR task force has promulgated several points to consider in managing difficult-to-treat RA. These "points" are unique in directing the rheumatologist's attention to the potential for misdiagnosis and the impact of comorbid conditions on what is perceived as poorly controlled RA.

Read Article
Spirometry study in 2,008 #RA patients - compared to controls, RA has a higher risk of restrictive Lung dz (OR 1.36, 95%CI 1.21,1.52) and obstructive LD (OR 1.21, 95%CI 1.07,1.37) independent of confounders like smoking https://t.co/UWViAZL6PO https://t.co/9OBz5ROKhw
Dr. John Cush @RheumNow( View Tweet )
Aug 19, 2021
Metanalysis of Colchicine in oronary artery disease (CAD) (13RCTs, n=13125), colchicine signif. reduces the risk of MI (OR 0.64) & CVA/TIA (OR 0.50), but has a higher rate of GI upset with no influence on all‐cause mortality (OR 0.96) https://t.co/CRDUFsc6lG

Dr. John Cush @RheumNow( View Tweet )

Aug 16, 2021

RheumNow Podcast – Booster Shots for COVID (8.13.2021)

Aug 13, 2021

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.




  1. In a head to head trial Upadacitinib was superior to Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis. 24wk DBRCT, 924 pts given either UPA 30/d vsDUP 300 EOW. ESI75 response@

Read Article
Biomarkers predict early ILD in systemic sclerosis: https://t.co/9z4Swjjy4p we need a biomarker for early disease!

Peter Nash @drpnash( View Tweet )

Aug 13, 2021

Rare Risk of Serious Adverse Events After COVID Vaccination

CDC/MMWR
Aug 10, 2021

The CDC had reported the Advisory Committee on Immunization Practices (ACIP) study of rare serious adverse events after COVID-19 vaccination and assert that the excessive morbidity and mortality from COVID-19 (and the protection afforded by vaccination) far exceeds the risk of rare safety

Read Article

Multimorbidity Impairs Responses in Rheumatoid Arthritis

Aug 03, 2021

A retrospective analysis of the ACR RISE registry shows that multimorbidity is not only common in patients with active rheumatoid arthritis (RA), but also impacts treatment choices and outcomes.



Analysis of active RA patients in the Rheumatology Informatics System for Effectiveness (

Read Article
×